B. Riley Has Positive Outlook for CNTA FY2024 Earnings

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Research analysts at B. Riley increased their FY2024 earnings per share estimates for Centessa Pharmaceuticals in a research report issued on Tuesday, November 12th. B. Riley analyst M. Mamtani now expects that the company will post earnings of ($1.54) per share for the year, up from their previous estimate of ($1.70). B. Riley currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.68) per share. B. Riley also issued estimates for Centessa Pharmaceuticals’ Q4 2024 earnings at ($0.40) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.55) EPS, FY2026 earnings at ($1.87) EPS and FY2027 earnings at ($2.18) EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05.

Several other equities research analysts also recently weighed in on CNTA. Guggenheim increased their price target on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. BMO Capital Markets increased their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. Oppenheimer reissued an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $11.00 to $26.00 in a research note on Thursday, September 19th. Finally, Jefferies Financial Group boosted their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $25.17.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA opened at $17.50 on Friday. Centessa Pharmaceuticals has a 52 week low of $5.58 and a 52 week high of $18.74. The company has a quick ratio of 13.29, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a fifty day moving average of $15.87 and a two-hundred day moving average of $12.07.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Large investors have recently bought and sold shares of the business. First Light Asset Management LLC acquired a new position in Centessa Pharmaceuticals during the first quarter worth $33,923,000. Farallon Capital Management LLC raised its position in shares of Centessa Pharmaceuticals by 438.0% during the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock worth $18,024,000 after purchasing an additional 1,625,000 shares during the last quarter. Driehaus Capital Management LLC lifted its stake in Centessa Pharmaceuticals by 89.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after buying an additional 987,997 shares in the last quarter. Perceptive Advisors LLC boosted its holdings in Centessa Pharmaceuticals by 27.6% in the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock worth $35,518,000 after buying an additional 850,000 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in Centessa Pharmaceuticals during the 2nd quarter worth approximately $4,064,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 4,169 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total transaction of $51,362.08. Following the completion of the transaction, the chief executive officer now directly owns 827,755 shares of the company’s stock, valued at approximately $10,197,941.60. This trade represents a 0.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 25,000 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $15.00, for a total transaction of $375,000.00. Following the completion of the sale, the insider now directly owns 223,369 shares in the company, valued at $3,350,535. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 325,031 shares of company stock valued at $5,213,043 in the last 90 days. Insiders own 11.59% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.